Argos Therapeutics

DURHAM, NC · Biotech · Acquired

Personalized dendritic cell immunotherapy for cancer

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · argostherapeutics.com

Sector: Biotech
Headquarters: DURHAM, NC
Latest Form D: $22M, Aug 2013
Total capital: $93.6M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $55.4M; 5 Form D · last Aug 2013; 158 months since last filing
Federal contracts: $38.2M; 1 award · Health and Human S; Rank in Biotech#24 of 4373
Granted patents: 11; 16 pending · first 2015; Rank in peer group#156 of 1449

Capital timeline

Latest events

Aug 2013Private capital raisedForm D · SEC · 5th filing$22M
Sep 2012Private capital raisedForm D · SEC · 4th filing$16M
Apr 2012Private capital raisedForm D · SEC · 3rd filing$9M
Jul 2011Private capital raisedForm D · SEC · 2nd filing$3.5M
Sep 2010Private capital raisedForm D · SEC · 1st filing$4.9M
Sep 2006Federal contractHealth and Human S · TAS::75 0885::TAS Hiv Vaccine Design And Development Teams Part B$38.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

48months

from Argos Therapeutics’s first federal award to its first private round.

First federal award · Sep 2006: Health and Human S · $38.2M
First Form D · Sep 2010: $4.9M · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#156 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Charles A. NicoletteResearcherExecutive OfficerLinked by 1 patent
Andrei A. PetrovDirectorNamed in SEC Form D filings
B. Jefferson ClarkDirectorNamed in SEC Form D filings
Brian R. UnderdownDirectorNamed in SEC Form D filings
David A. GryskaDirectorNamed in SEC Form D filings
Douglas A. PlessingerExecutive OfficerNamed in SEC Form D filings

Show all 16 people

Frederick M. MiesowiczExecutive OfficerNamed in SEC Form D filings
Hubert D. BirnerDirectorNamed in SEC Form D filings
Ines Jefferson HolzbaurDirectorNamed in SEC Form D filings
Jean A. LamarreDirectorNamed in SEC Form D filings
Jeffrey D. AbbeyExecutive Officer, DirectorNamed in SEC Form D filings
Lori A. HarrelsonExecutive OfficerNamed in SEC Form D filings
Michel Jefferson GrecoDirectorNamed in SEC Form D filings
Monique A. LaliberteDirectorNamed in SEC Form D filings
Philip R. TracyDirectorNamed in SEC Form D filings
Sander Jefferson van DeventerDirectorNamed in SEC Form D filings

What it has protected

USPTO · 11 granted of 27

Jan 22, 2019GrantedMature Dendritic Cell Compositions And Methods For Culturing SameUSPTOUS 10,184,108
Jul 17, 2018GrantedCentrifuge Vessels With A Center Mound And An Internal Elongate Tube Suitable For Live Cell Processing And Associated Systems And MethodsUSPTOUS 10,022,731
Jan 30, 2018GrantedStrain-Independent Amplification of Pathogens and Vaccines TheretoUSPTOUS 9,879,053

Show all 27 patent records

Mature Dendritic Cell Compositions And Methods For Culturing SameJan 22, 2019 · US 10,184,108Granted
Centrifuge Vessels With A Center Mound And An Internal Elongate Tube Suitable For Live Cell Processing And Associated Systems And MethodsJul 17, 2018 · US 10,022,731Granted
Strain-Independent Amplification of Pathogens and Vaccines TheretoJan 30, 2018 · US 9,879,053Granted
Use Of Soluble Forms Of CD83 And Nucleic Acids Encoding Them For The Treatment Or Prevention Of DiseasesAug 15, 2017 · US 9,732,140Granted
Methods Of Processing SamplesMay 2, 2017 · US 9,638,707Granted
Mature Dendritic Cell Compositions And Methods For Culturing SameJan 31, 2017 · US 9,556,455Granted
Processing ContainersDec 27, 2016 · US 9,527,074Granted
Mature Dendritic Cell Compositions and Methods for Culturing SameDec 20, 2016 · US 9,523,077Granted
Dendritic Cell Compositions and MethodsSep 20, 2016 · US RE46,152Granted
Processing ContainersAug 9, 2016 · US 9,409,178Granted
Dendritic Cell Compositions and MethodsApr 14, 2016 · Application 14879336Pending
Use of CD83 in Combination TherapiesJan 14, 2016 · Application 14872356Pending
Apparatus For Measuring Volume Of A FluidMay 26, 2015 · US 9,040,303Granted
Dendritic Cell Compositions and MethodsMay 14, 2015 · Application 14307991Pending
Tscm Cells And Methods For UseApplication PCTUS2015016797Pending
Automated Processing Systems, Apparatus, Methods And Related DevicesApplication 62531918Pending
Methods and Uses for Dendritic Cell TherapyApplication 62582853Pending
Methods of Making Natural Killer Cells and Uses ThereofApplication 62677019Pending
Automated Processing Systems, Apparatus, Methods And Related DevicesApplication PCTUS2018041568Pending
Methods And Uses For Dendritic Cell TherapyApplication PCTUS2018059610Pending
Centrifuge Vessels Suitable For Live Cell Processing And Associated Systems And MethodsApplication PCTUS2013022512Pending
Novel Soluble CD83 Polypeptides, Formulations And Methods Of UseApplication PCTUS2009003174Pending
Use Of CD83 In Combination TherapiesApplication PCTUS2007018048Pending
Strain Independent Amplification Of Pathogens And Vaccines TheretoApplication PCTUS2005032710Pending
Cationic Peptide-mediated TransformationApplication PCTUS2005022705Pending
Bispecific Antibodies that Modulate TLR-4 Signaling and Uses ThereofApplication 62418713Pending
Mrna Transfected Antigen Presenting CellsApplication PCTUS2004039535Pending

Sciome LLCSimilar federal contract value in Biotech · $39.3M in contracts
Soligenix, IncSimilar federal contract value in Biotech · $39.1M in contracts
PROFECTUS BIOSCIENCES, INC.Similar federal contract value in Biotech · $38.3M in contracts
APTITUDE MEDICAL SYSTEMS INCSimilar federal contract value in Biotech · $36.5M in contracts
AMGEN INCSimilar federal contract value in Biotech · $34.9M in contracts
PLUS THERAPEUTICS, INC.Similar federal contract value in Biotech · $33.8M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.